KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD.

Mingchao Shi, Fengna Chu, Tao Jin, Jie Zhu

CNS Neurosci Ther 28(7) 981-991

PMID35426485
PMCIDPMC9160456
DOI10.1111/cns.13836
发表日期2022-04-15
摘要

摘要

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune inflammatory demyelinating disorder of the central nervous system (CNS), which is a severely disabling disorder leading to devastating sequelae or even death. Repeated acute attacks and the presence of aquaporin-4 immunoglobulin G (AQP4-IgG) antibody are the typical characteristics of NMOSD. Recently, the phase III trials of the newly developed biologicals therapies have shown their effectiveness and good tolerance to a certain extent when compared with the traditional therapy with the first- and second-line drugs. However, there is still a lack of large sample, double-blind, randomized, clinical studies to confirm their efficacy, safety, and tolerability. Especially, these drugs have no clear effect on NMOSD patients without AQP4-IgG and refractory patients. Therefore, it is of strong demand to further conduct large sample, double-blind, randomized, clinical trials, and novel therapeutic possibilities in NMOSD are discussed briefly here.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。